表紙
市場調査レポート

グルカゴン様ペプチド-1(GLP-1)受容体作動薬:ターゲットパイプラインおよびステークホルダー分析(2012年)

Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists - A Target Pipeline and Stakeholder Analysis 2012

発行 La Merie Publishing 商品コード 235119
出版日 ページ情報 英文 231 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。
Back to Top
グルカゴン様ペプチド-1(GLP-1)受容体作動薬:ターゲットパイプラインおよびステークホルダー分析(2012年) Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists - A Target Pipeline and Stakeholder Analysis 2012
出版日: 2012年03月29日 ページ情報: 英文 231 Pages
概要

当レポートでは、グルカゴン様ペプチド-1(GLP-1)受容体作動薬の商業的側面と臨床分野での動向について調査分析し、2型糖尿病のインクレチンによる治療動向、治療コスト・医師による好み・患者人口など、GLP-1受容体作動薬を取り巻くビジネス環境、GLP-1受容体作動薬のパイプラインにおける動向、主要企業のプロファイルなどをまとめ、概略以下の構成でお届けいたします。

第1章 概要

第2章 エグゼクティブサマリー

第3章 背景:2型糖尿病のインクレチンベースの治療

第4章 インクレチンベースの治療の商業的経験

第5章 GLP-1R作動薬のビジネス環境

  • GLP-1R作動薬:ターゲットバリデーションと臨床POC
  • GLP-1R作動薬の月額治療コスト
  • GLP-1R作動薬:医師の好み・優先度
  • 糖尿病患者の人口
  • GLP-1R作動薬市場の成長推進因子・阻害因子
  • アンメットニーズと差異化
  • GLP-1R作動薬プログラムの評価:商取引別

第6章 GLP-1受容体作動薬のパイプライン

  • パイプラインアプローチの概要
  • 上市間近のGLP-1R作動薬
  • 1日1回皮下投与型GLP-1R作動薬
  • 長時間作用皮下投与型GLP-1R作動薬
  • 非侵襲性ペプチドGLP-1R作動薬
  • 経口小分子GLP-1R作動薬
  • インスリンとGLP-1R作動薬
  • デュアルターゲットグルカゴン/GIP&GLP-1R作動薬
  • GLP-1受容体作動薬のパイプラインの評価

第7章 企業プロファイル

第8章 リファレンス

付録:薬剤プロファイル

  • Albiglutide (GSK716155)
  • Bydureon
  • CJC-1134-PC
  • CM3
  • CNTO3649 / CNTO736
  • DA-3091
  • Dulaglutide (LY2189265)
  • Liraglutide
  • Lixisenatide
  • PF-04856883

競合分析

  • 代謝性疾患におけるGLP-1受容体作動薬
  • その他の疾患におけるGLP-1受容体作動薬
  • 中断されたGLP-1受容体作動薬プロジェクト
目次
Product Code: LMFR0006

Abstract

Summary

This report "Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists - A Target Pipeline and Stakeholder Analysis 2012" published in March 2012 provides a compilation of business, commercial, clinical and scientific information about GLP-1 receptor agonists. A comprehensive analysis of the state of the art and key trends guides the reader through this emerging antidiabetic drug class. Scientific and technological approaches as well as molecules in the target pipeline of GLP-1 receptor agonists are described and assessed. A critical appraisal of the clinical results of advanced GLP-1 receptor agonist projects and products is provided..

Scope of the report

  • Commercial experience with incretin-based therapeutics
  • Monthly treatment costs of GLP-1R agonists
  • Physician preferences and priorities for GLP-1R agonists
  • GLP-1R agonist market drivers and restraints
  • Unmet needs and differentiation between GLP-1R agonists
  • Valuation of GLP-1R agonist programs by business transactions
  • Next-to-market GLP-1R agonists
  • Once-daily subcutaneous GLP-1R agonists
  • Long-acting subcutaneous GLP-1R agonists
  • Non-invasive peptide GLP-1R agonists
  • Oral small molecule GLP-1R agonists

Combinatgion and dual target Glucagon/GIP and GLP-1R agonists Although the first glucagon-like peptide-1 receptor (GLP-1R) agonist was already approved in 2005, it was the launch of the once daily GLP-1R agonist Victoza from Novo Nordisk in 2010 which boosted the market size to US$ 1.7 bln in 2011. Victoza became a blockbuster in its second year on the market. The unique feature of weight reduction associated with the use GLP-1R agonists clearly differentiates this antidiabetic drug class from other established antidiabetics. The profound blood glucose lowering effect without significant hypoglycemia made GLP-1R agonists to a strongly emerging antidiabetic drug class. Gastrointestinal side effects such as nausea, vomiting and diarrhea seem to be associated with the pharmacologic effect of GLP-1R agonism.

The clinically and commercially validated target makes GLP-1 attractive for follow-on molecules with improved properties. Analysis of the GLP-1R agonist pipeline revealed in addition to the three approved and marketed GLP-1R agonists (Byetta, Victoza and once-weekly Bydureon) 66 R&D projects including eight life cycle versions. The vast majority of new GLP-1R agonists are designed to have improved features which mainly are based on convenience (less frequent administration or non-invasive/oral administration). Molecules with less frequent subcutaneous administration make out the majority (33) with 13 projects in clinical phases II or III, while 18 R&D projects are directed to non-invasive or oral administration of GLP-1R agonists with only one program in phase II. A strongly emerging third cluster of novel GLP-1 R agonists is that of GLP-1R agonists in combination with insulin at a fixed ratio and of co-agonists or dual targeting molecules, i.e. GLP-1R agonists which also act at the receptor of glucagon (mostly) or GIP.

Table of Contents

1 Overview

2 Executive Summary

3 Background of incretin-based therapy of type 2 diabetes

4 Commercial experience with incretin-based therapeutics

5 Business environment for GLP-1R Agonists

  • 5.1 Target validation and clinical proof-of-concept of GLP-1R agonists
  • 5.2 Monthly treatment costs of GLP-1R agonists
  • 5.3 Physician preferences and priorities for GLP-1R agonists
  • 5.4 Diabetes patient population
  • 5.5 GLP-1R agonist market drivers and restraints
  • 5.6 Unmet needs and differentiation between GLP-1R agonists
  • 5.7 Valuation of GLP-1R agonist programs by business transactions

6 GLP-1 Receptor Agonist Pipeline

  • 6.1 Overview of approaches in GLP-1R agonist pipeline
  • 6.2 Next-to-market GLP-1R agonists
  • 6.3 Once-daily subcutaneous GLP-1R agonists
  • 6.4 Long-acting subcutaneous GLP-1R agonists
  • 6.5 Non-invasive peptide GLP-1R agonists
  • 6.6 Oral small molecule GLP-1R agonists
  • 6.7 Insulin and GLP-1R agonists
  • 6.8 Dual target Glucagon/GIP and GLP-1R agonists
  • 6.9 Assessment of the GLP-1 receptor agonist pipeline

7 Company Profiles

  • Addex Pharmaceuticals
  • Alkermes
  • Altea Therapeutics
  • Alteogen
  • Amylin Pharmaceuticals
  • Arisaph Pharmaceuticals
  • Arisgen
  • Ascendis Pharma
  • Bio-ker (Multimedica)
  • Boehringer Ingelheim
  • BTG (Biocompatibles International)
  • Camurus
  • ConjuChem
  • Diartis Pharmaceuticals (Amunix)
  • Domain Therapeutics
  • Dong-A Pharmaceuticals
  • Eli Lilly
  • Emisphere Technologies
  • GlaxoSmithKline (Human Genome Science)
  • Hanmi Pharmaceutical
  • Intarcia Therapeutics
  • Johnson & Johnson (Centocor)
  • Lanthio Pharma
  • LG Life Sciences
  • MannKind
  • Merck & Co.
  • Novo Nordisk
  • Oramed Pharmaceuticals
  • Peptron & Neopharm
  • Pfizer
  • PharmaIn
  • PhaseBio
  • Poxel
  • PROLOR Biotech
  • Proxima Concepts (Diabetology)
  • Receptos
  • Roche
  • Sanofi-Aventis
  • Sanwa Kagaku Kenkyusho
  • Teijin
  • Transition Therapeutics
  • TransPharma Medical (assets acquired by Syneron)
  • Transtech Pharma
  • Uni-Bio Science
  • Zealand Pharma
  • Zydus Cadila

8 References

9 Tables

  • Table 1 Adverse effects and limitations of oral antidiabetics
  • Table 2 Byetta Sales 2005 - 2011
  • Table 3 GLP-1 Receptor Agonist Market
  • Table 4 DPP-IV Inhibitor Sales 2011
  • Table 5 Comparative Drug Profiles of Marketed GLP-1 Agonists
  • Table 6 Monthly treatment costs of GLP-1R Agonists
  • Table 7 Short- and Mid-Term GLP-1R Agonist Market Drivers and Restraints
  • Table 8 Differentiation factors for GLP-1R Agonists
  • Table 9 Overview of Approaches in Pipeline of GLP-1R Agonists
  • Table 10 Approaches followed by Big Pharma in R&D of GLP-1R agonists
  • Table 11 Potential Next-to-Market GLP-1R Agonists
  • Table 12 Daily Subcutaneous GLP-1 Receptor Agonists
  • Table 13 Technologies to increase the molecular size of GLP-1R agonists
  • Table 14 Weekly and Bi-weekly SC GLP-1 Receptor Agonists
  • Table 15 Comparative Drug Profiles of Advanced GLP-1 Agonists
  • Table 16 Monthly and Longer SC GLP-1 Receptor Agonists
  • Table 17 Non-Invasive Peptide GLP-1 Receptor Agonists
  • Table 18 Oral Small Molecule GLP-1 Receptor Agonists
  • Table 19 Fixed-Ratio Insulin and GLP-1 Receptor Agonist Combinations
  • Table 20 Dual Targeting GCG/GIP and GLP-1R Agonists
  • Table 21 Amylin pipeline of exenatide-based GLP-1R agonists
  • Table 22 GlaxoSmithKline's pipeline of GLP-1R agonists
  • Table 23 Effects of ITCA 650 on HbA1c and body weight
  • Table 24 Novo Nordisk's GLP-1 Receptor Agonist Pipeline
  • Table 25 Pfizer's pipeline of GLP-1 receptor agonists
  • Table 26 Overview of taspoglutide side effects at 24 weeks:
  • Table 27 Sanofi's GLP-1 Receptor Agonist Pipeline
  • Table 28 Sanofi's phase III program of lixisenatide

ADDENDUM

A Executive Drug Profiles

  • Albiglutide (GSK716155)
  • Bydureon
  • CJC-1134-PC
  • CM3
  • CNTO3649 / CNTO736
  • DA-3091
  • Dulaglutide (LY2189265)
  • Liraglutide
  • Lixisenatide
  • PF-04856883

B Competitor Analysis

  • GLP-1 Receptor Agonists in Metabolic Diseases
  • GLP-1 Receptor Agonists in Other Diseases
  • Discontinued GLP-1 Receptor Agonist Projects
Back to Top